BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27441415)

  • 21. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
    Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
    Lu W; Wei H; Li M; Wang H; Liu L; Zhang Q; Liu L; Lu S
    Mol Med Rep; 2015 Jul; 12(1):1219-24. PubMed ID: 25815786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
    Myers MB; Banda M; McKim KL; Wang Y; Powell MJ; Parsons BL
    Neoplasia; 2016 Apr; 18(4):253-63. PubMed ID: 27108388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunophenotypes and gene mutations in colorectal precancerous lesions and adenocarcinoma].
    Huang WT; Qiu T; Ling Y; Shi SS; Guo L; Zheng B; Lü N; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):655-9. PubMed ID: 24433726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in PIK3CA are infrequent in neuroblastoma.
    Dam V; Morgan BT; Mazanek P; Hogarty MD
    BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.
    Kosmidou V; Oikonomou E; Vlassi M; Avlonitis S; Katseli A; Tsipras I; Mourtzoukou D; Kontogeorgos G; Zografos G; Pintzas A
    Hum Mutat; 2014 Mar; 35(3):329-40. PubMed ID: 24352906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.
    Tilch E; Seidens T; Cocciardi S; Reid LE; Byrne D; Simpson PT; Vargas AC; Cummings MC; Fox SB; Lakhani SR; Chenevix Trench G
    Breast Cancer Res Treat; 2014 Jan; 143(2):385-92. PubMed ID: 24318467
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Goto K; Maeda D; Kudo-Asabe Y; Hibiya T; Hayashi A; Fukayama M; Ohashi K; Goto A
    J Clin Pathol; 2017 May; 70(5):424-427. PubMed ID: 27742746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
    Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
    Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.
    Simi L; Pratesi N; Vignoli M; Sestini R; Cianchi F; Valanzano R; Nobili S; Mini E; Pazzagli M; Orlando C
    Am J Clin Pathol; 2008 Aug; 130(2):247-53. PubMed ID: 18628094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway.
    Volckmar AL; Leichsenring J; Flechtenmacher C; Pfarr N; Siebolts U; Kirchner M; Budczies J; Bockmayr M; Ridinger K; Lorenz K; Herpel E; Noske A; Weichert W; Klauschen F; Schirmacher P; Penzel R; Endris V; Stenzinger A
    Genes Chromosomes Cancer; 2017 Jan; 56(1):11-17. PubMed ID: 27438523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
    Martin V; Botta F; Zanellato E; Molinari F; Crippa S; Mazzucchelli L; Frattini M
    Histol Histopathol; 2012 Jun; 27(6):785-92. PubMed ID: 22473698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Traditional serrated adenoma of the colorectum: clinicopathologic implications and endoscopic findings of the precursor lesions.
    Kim MJ; Lee EJ; Suh JP; Chun SM; Jang SJ; Kim DS; Lee DH; Lee SH; Youk EG
    Am J Clin Pathol; 2013 Dec; 140(6):898-911. PubMed ID: 24225759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas.
    Pai RK; Mojtahed K; Pai RK
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):133-40. PubMed ID: 21307665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo.
    Hafner C; Stoehr R; van Oers JM; Zwarthoff EC; Hofstaedter F; Landthaler M; Hartmann A; Vogt T
    Br J Dermatol; 2009 Mar; 160(3):546-51. PubMed ID: 19076977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai.
    Wang YL; Dai X; Li YD; Cheng RX; Deng B; Geng XX; Zhang HJ
    Genet Mol Res; 2015 Nov; 14(4):14840-6. PubMed ID: 26600545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.